The U.S. Patent and Trademark Office has removed a senior legal adviser from a high-profile case after she tweeted contentious remarks about the right of AIDS activists to challenge a patent-term extension sought by Gilead Sciences (GILD) for an HIV medicine.
A spokesman for the federal agency told us that Mary Till, a 14-year employee who reviews extension requests, is “no longer working on the matter.”
Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
May one observe that employees of the Executive branch should realize that Twitter can be bad for your career – with one conspicuous exception that comes to mind.